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Abstract
Background: Current inventories on quality of life used in oncology mainly focus on functional
aspects of patients in the context of disease adaption and treatments (side) effects (EORTC QLQ
C30) or generically the status of common functions (Medical Outcome Study SF 36). Beyond
circumscribed dimensions of quality of life (i.e., physical, emotional, social, cognitive etc.), there is
a lack of inventories which also address other relevant dimensions such as the 'sense of coherence'
(SOC) in cancer patients. SOC is important because of its potential prognostic relevance in cancer
patients, but the current SOC scale has mainly been validated for psychiatric and psychosomatic
patients. Our two-step validation study addresses the internal coherence (ICS) scale, which is based
on expert rating, using specific items for oncological patients, with respect to its reliability, validity
and sensitivity to chemotherapy.
Methods: The items were tested on 114 participants (57 cancer patients and a matched control
group), alongside questions on autonomic regulation (aR), the Hospital Anxiety and Depression
Scale (HADS), self-regulation (SRQ) and Karnofsky the Performance-Index (KPI). A retest of 65
participants was carried out after a median time span of four weeks.
In the second part of the study, the ICS was used to assess internal coherence during chemotherapy
in 25 patients with colorectal carcinoma (CRC) and 17 breast cancer patients. ICS was recorded
before, during and 4 – 8 weeks after treatment.
Results: The 10-item scale of 'internal coherence' (ICS) shows good to very good reliability:
Cronbach-α r = 0.91, retest-reliability r = 0.80. The ICS correlates with r = 0.43 – 0.72 to the
convergence criteria (all p < 0.001). We are able to show decreased ICS-values after the third cycle
for CRC and breast cancer patients, with a subsequent increase of ICS scores after the end of
chemotherapy.
Conclusion: The ICS has good to very good reliability, validity and sensitivity to chemotherapy.
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Background
Since quality of life has gained increasing importance in
clinical oncology over the last 15 years, current quality of
life inventories now focus on physical, mental, cognitive,
social and other dimensions along with chemotherapeu-
tical effects. These comprise the EORTC QLQ C30 [1] of
the European Organisation for Research on Treatment of
Cancer, including additional scales for specific types of
tumours [2] or the Functional Assessment of Cancer Ther-
apy – FACT [3] which, next to the basic module, also con-
tains symptom-specific supplementary modules [4].
Generic questionnaires such as the Medical Outcome
Study SF-36, which is also used for oncologic patients,
capture the rehabilitative, physical, emotional and social
functional status [5].
New studies have yielded some evidence that question-
naires capturing the individual skills of adaptation such as
the 'sense of coherence' [6] or 'self-regulation' (Grossarth-
Maticek 1999) could be more appropriate as prognostic
tools in oncology or in other chronic conditions than con-
ventional health-related quality of life (HRQL) scales [7].
However, inventories which capture the 'Sense of Coher-
ence' (SOC) based on Antonovsky's concept of salutogen-
esis have mainly been validated in psychosomatic and
psychiatric patients [6,8]. Antonovsky's initial question
was: What keeps a person healthy? For Antonovsky,
health is a continuum between total disease (dis-ease)
and complete health (ease). Salutogenesis is a concept
based around stress and resilience. The question of salu-
togenesis contrasts with a central question of scientific
medicine into pathogenesis: What makes a person ill? [6].
The SOC is based on three components which are consid-
ered prerequisites for salutogenesis: comprehensibility,
meaningfulness and manageability.
1) According to Antonovsky, these three factors determine
to what extent a person can rely an existing, enduring but
also dynamic feeling of trust, which gives structure to the
course of internal as well as external events and makes
them understandable.
2) These resources have to be available when required and
3) the situation must be understood as challenges which
deserve rising to [9].
New epidemiological studies have articulated the poten-
tial prognostic relevance of SOC for cancer patients [7].
However, Antonovsky was a sociologist and did not
extend his work to people with chronic illness, focusing
instead on survivors of the Holocaust. Thus, although the
current SOC scale includes general questions about life
style, attitudes to life, and mental health [10] which are
relevant to all groups of people, it does not address phys-
ical health. But rather than containing references to phys-
iological parameters as postulated by Antonovsky [8,9],
due to its origin, it focuses in particular on mental health.
Already, in 1923 a first medical approach to salutogenesis
was discussed [11]. All in all, it therefore there is a need to
develop a questionnaire with a stronger focus on patients
with chronic diseases, particularly cancer.
Here we report a two stage validity study which aimed to
validate the ICS which was developed based on a non-
standardised open questioning process of cancer patients
before starting the study and expert ratings from questions
on disease management, outlook on life and drive, per-
ception of health and thermoregulation for oncological
patients. We followed development of the instrument by
testing reliability, and validity of construct and content, as
well as its responsiveness to chemotherapy.
Methods
On the basis of a former non-standardised questioning
process in 2001 in our centre of tumour therapy, cancer
patients described the following symptoms as their major
complaints under chemo- and radiotherapy: 1) fatigue, 2)
lack of motivation, 3) asthenia, 4) sleepiness, 5) lack of
concentration and 6) cogitation, 7) disturbance of mem-
ory, 8) depressive symptoms, 9) visual, 10) acoustic, 11)
olfactory and 12) gustatory hypersensitivity, 13) feeling
indifferent, 14) feeling being not really present, 15) feel-
ing not being coherent, 16) feeling discouraged, .17) feel-
ing uncomfortable, 18) doing activities in a "mechanical
manner", 19) having cold hands and feet, 20) often and
quick freezing. The symptoms 1 – 7 were integrated in the
parallel development process in the CFS-D [19], the
symptoms 9–13 have been integrated in the question-
naire as single items.
Based on the symptoms 13 – 20, a group of experts
(oncologist, internist, gastroenterologist, somnologist,
general practitioner and statistician) formulated twelve
items on the topics of meaningfulness, manageability and
resilience in dealing with cancer disease and formation of
perspective. According to our experience in cancer
patients, we also integrated items on heat regulation,
because a feeling of comfort and well-being is often asso-
ciated with good thermoregulation being a precondition
on the subject of inner coherence.
Study 1: item detection, reliability and validity
We carried out this study in the Departments of General
Internal Medicine and Gastroenterology at the Gemein-
schaftskrankenhaus Havelhöhe (Berlin), as well as in the
specialist oncology practice at the hospital between Janu-
ary 2003 and February 2004.Health and Quality of Life Outcomes 2009, 7:59 http://www.hqlo.com/content/7/1/59
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Consecutively recruited patients with histologically con-
firmed malignant tumours were matched according to age
(± 5 years) and gender with participants of a healthy con-
trol group who had no known acute or chronic disease.
Table 1 shows the demographic, table 2 the clinical and
treatment characteristics of the participants. Participants
with malignancies had a broad range of tumour localisa-
tions (table 3). At the time of being surveyed, at least two
weeks had elapsed since a participant's last operation,
chemotherapy or radiotherapy session. Further exclusion
criteria were patients with a Karnofsky's Index (KPI) <
50%, patients aged < 18 years or > 85 years, patients with
a manifest psychosis or uncontrollable pain.
Participants in the control group were recruited opportun-
istically from hospital staff and their families. Any history
of malignancy or severe chronic conditions was a criterion
for exclusion.
After the study was explained and consent was obtained,
the ICS questionnaire was administered. The target for the
test-retest analysis was at least 50% of all participants. The
questionnaire was re-administered opportunistically
without rejection on 65 participants (57.3%) after a
median of four weeks (mean of 5.2 weeks, SD = 4.2).
Next to the 12 ICS items (table 4) the following question-
naires were conducted:
1) The short questionnaire on 'self-regulation' (SRQ) is a
scale with 16 items in two subscales for measuring self-
regulation and health-building activity with a six-point-
Likert scale. The 16 items are added and divided by 16 to
obtain a total score. Subscale 1 is termed "Ability to
Change Behaviour in order to reach goals", and subscale
2 "Achieve Satisfaction and Well-Being", which thus has a
hedonistic connotation. Higher scores indicate better self-
regulation. The validity and reliability of the sum and sub-
scales are satisfactory until very good: Cronbach-alpha =
0.80 – 0.95 (and test-retest reliability = 0.73 – 0.82). We
used this scale because of its conceptual congruence (con-
vergent validity) with aspects of internal coherence
[12,13]
2) The long version questionnaire on 'autonomic regula-
tion' (aR) measures the autonomic functioning of an indi-
vidual with an 18-item scale in three subscales
(orthostatic-circulatory, rest/activity regulation and diges-
tive). AR measures with a three point Likert-scale (18 –
54) with a satisfactory/good reliability and good validity
[14,15]. Questions on thermoregulation are integrated
into this scale, so we used it to measure convergent valid-
ity of items concerning heat regulation [15].
3) The German version of the 'Hospital Anxiety and
Depression Scale' (HADS-D) consists of 14 items (7 for
anxiety and 7 for depression) on which people rate on a
four-point Likert scale (0–21 both). Higher scoring indi-
cate more symptoms, ≥ 11 points anxiety or depression
are probable, ≥ 8 – 10 possible cases, < 7 no cases. The
HADS is highly reliable and valid and is an extensively
used scale in internal medicine research [16,17].
4) The Karnofsky Performance-Index (KPI) [18] which is
a general and robust indicator of physical functioning
daily life.
5) Questions on autonomic state and heat sensitivity were
also collected [15].
Results of the co-validation procedure of the German ver-
sion of the Cancer Fatigue Scale (CFS-D) have been pub-
lished elsewhere [19].
Moreover, we documented the last haemoglobin level in
the blood (g/dl) before inclusion of all tumour patients. A
retest was carried out on 65 participants after a median of
4 weeks.
Table 1: Sociodemographic overview of the participants of studies 1 and 2
Study 1 Study 2
Cancer Control BC 1 CRC 3
Age (y) mean ± SD 58.8 ± 11.6 59.9 ± 10.3 54.3 ± 11.6 62.4 ± 10.6
min/max 30/83 32/81 37/71 33/76
Gender w o m e n 4 14 11 71 3
men 16 16 0 12
Marital status married 41 20 4 17
s t a b l e  p a r t n e r s h i p 2443
s i n g l e 2621
divorced 7 11 4 1
w i d o w e d 5613
missing 0 10 2 0Health and Quality of Life Outcomes 2009, 7:59 http://www.hqlo.com/content/7/1/59
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Study 2: ICS responsiveness for chemotherapy treatment
From April 2003 to March 2007, the Centre for Tumour
Therapy at the Gemeinschaftskrankenhaus Havelhöhe,
the oncological practice Öschelbronn and the oncological
practice Havelhöhe carried out study 2 to capture respon-
siveness of the ICS questionnaire to chemotherapy treat-
ment. Consecutively recruited breast cancer and colorectal
carcinoma (CRC) patients were examined before or dur-
ing adjuvant or palliative chemotherapy with mistletoe
therapy examining ICS responsiveness.
The following groups were formed in the process:
1) Breast cancer patients who received adjuvant comple-
mentary treatment with standardized and commercially
available whole plant extracts from Viscum album L. (mis-
tletoe) as standard therapy from the first cycle of chemo-
therapy (B) or
2) The colorectal cancer (CRC) group (C) was also sur-
veyed prior to the first cycle of chemotherapy with adju-
vant mistletoe therapy.
After explanation of the procedure and obtaining
informed consent, the following criteria were applied to
both groups for adjuvant or initially curatively conceived
or palliative chemotherapy with good general condition
Table 2: Overview of tumour stage, diagnosis duration, Karnofsky performance index, haemoglobin and therapy
Study 1: Cancer group Study 2: BC CRC
Metastasis or generalised stage
yes 35 (61.4%) 2 3
No 24 (38.6%) Stage 1 3 0
Stage 2 8 2
Stage 3 4 18
missing 0 2
Initial diagnosis (years) Initial diagnosis (months)
Mean (SD) 2.9 (3.1) 1.3 (1.0) 1.4 (0.5)
Median 2.0 1.0 1.0
Min/Max 0/12 1/5 1/2
Karnofsky-Index (%)
Mean (SD) 81.8 (11.6) 86.7 (10.5) 88.7 (9.2)
Median 90 90 90
Haemoglobin (gr/dl)
Mean (SD) 12.1 (1.84) 13.0 (1.28) 13.7 (6.8)
Median 12.5 13.2 12.65
Anemia (<12) 22 (38.5%) 2 (11.1%) 9 (36.0%)
Therapies at the point of questioning Therapies after first questioning
Operation because of cancer 39 (68.4%) 14 (82.3%) 25 (100%)
Chemotherapy 31 (54.4%) 17 (100%) 25 (100%)
Chemotherapy Scheme
CMF+RAD 2
EC or EC+RAD 7
EC/CMF or EC/CMF +RAD 3
FEC or FEC + RAD 1
EC/Tac 2
Tac/other 2
5FU (Mayo mod/Ardalan) 5
5FU + RAD 5
FOLFOX 12
FOLFOX+RAD 1
OXALI mono or others 2
Radiotherapy 14 (24.6%) 6 (35.2%) 7 (28.0%)
Antihormonal therapy 13 (22.8%) 6 (35.2%) 0 (0)
Mistletoe therapy 57 (100%) 17 (100) 25 (100)Health and Quality of Life Outcomes 2009, 7:59 http://www.hqlo.com/content/7/1/59
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and a KPI ≥ 70%. The oncologically scheduled chemo-
therapy, radiotherapy or mistletoe therapy was not
impacted or changed by the study so that this second part
of the validation study only measured the changing sensi-
tivity (responsiveness) of the instruments. Thus, study 2 is
not a pharmacological study to test effectiveness of the
treatment which was administered as a routine procedure,
but as a sensitivity testing of the instrument.
For this purpose, the surveys were carried out 1 – 5 days
prior to the start of chemotherapy (B, C), 1 – 5 days after
the third cycle as well as 4 – 8 weeks after the end of chem-
otherapy using the ICS, CFS-D [19], State autonomic reg-
ulation aR [20] and EORTC QLQC30 [1]. For KPI, stage of
cancer, surgery and chemotherapy see table 2. The data on
CFS-D, State aR and EORTC are published elsewhere.
Statistics of both parts of the study
A reliability analysis of all 12 items of the ICS was carried
out for all participants of study 1 with SPSS 15.0 to check
for item-item and item-total-correlation of r ≥ 0.40 and a
Cronbach's-α-reliability of r ≥ 0.70. The test-retest reliabil-
ity was assessed with the 65 persons completing the ques-
tionnaire by Spearman's rank correlation. For all
participants, we performed an orthogonal principal com-
ponents analysis (rotation: varimax with Kaiser normali-
sation). We used the self-regulation questionnaire as a
main convergence criterion because it's two dimensional
scale is measuring the adaptive capacitiy. "Ability to
Change Behaviour", and "Achieve Satisfaction and Well-
Being" dealing with oncological disease. In addition, we
performed a Spearman's rank correlation analysis for the
whole sample, testing for associations between the ICS
sum- and subscales on one hand and the assumed conver-
gence criteria on the other. We assessed the discriminant
validity by applying the Mann-Whitney U-test to check
whether ICS sum- and subscales and self-regulation are
differentiating between cancer and healthy controls, and
by comparing both results. We estimated the responsive-
ness in measuring
1) chemotherapy sensitivity within the B and C group
with the one-sided Wilcoxon's signed-rank test as well
between first and second as second and third test-point.
Results
Part 1 of the study
Participants
59 consecutive patients with malignant conditions and 59
healthy controls were invited to participate in the study 1.
In total, 114 persons agreed to participate (recruitment
rate of 97%). From the 57 recruited cancer patients, we
had 41 men and 16 women with a mean age of 59.3 years.
Age and gender matching with the comparison group was
successful (table 1).
Twenty-two patients had no metastases, 35 had a meta-
static or generalized disease. The median KPI at the time
of recruitment was 90%. The duration of the disease was
on average 2.9 years. The mean haemoglobin (Hb) level
was 12.1 g/dl (SD = 1.84). Further participant details are
listed in table 2.
Analysis of reliability
All 12 items were checked: In the first step "when I felt
warm I felt well" and "I had nightmares" were eliminated
because of insufficient item-total correlation (0.20 and
0.32 respectively). The other 10 items fulfilled all reliabil-
ity criteria:
Item-Item-correlations: r = 0.49, min – max = 0.25 – 0.84.
The mean of item-variance is = 1.06 (min – max = 0.76 –
1.28). The corrected item-total correlation is:
rtr = 0.53 – 0.82. Cronbach's-α of the ICS sumscore rα =
0.91, retest-reliability rrt = 0.80 (p < 0.001) (table 4).
Principal component analysis
Primary factor analysis points to a two-principal-compo-
nents model. The two-principal-components model (8
resp. 2 items) exhibits the attractive feature of unambigu-
ousness in factor loading. Principal component 1 (inner
Table 3: Diagnosis of cancer patients in study 1
Included N %
B-chronic lymphatic leukaemia (B-CLL) 1 1.8
B-cell Lymphoma (NHL) 2 3.5
Breast cancer 16 28.1
Bronchial carcinoma (NSCLC) 5 8.8
Carcinoma unclear primary (CUP) 1 1.8
Cervix carcinoma 1 1.8
Colon carcinoma 4 7.0
Gallbladder carcinoma 1 1.8
Hypernephroma 1 1.8
Leiomyosarcoma 1 1.8
Melanoma 1 1.8
Ovarian carcinoma 2 3.5
Ovarian sarcoma 1 1.8
Pancreatic cancer 2 3.5
Pharyngeal cancer 1 1.8
Plasmocytoma 4 7.0
Pleural mesotelioma 3 5.3
Prostatic cancer 3 5.3
Rectum carcinoma 2 3.5
Thymic carcinoma 1 1.8
Thyroid carcinoma 2 3.5
Tonsillar carcinoma 1 1.8
Urethral cancer 1 1.8
Total 57 100.0H
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Table 4: Items of the ICS
Item Answer Scores Mean values ± SD Item-Total 
Correlation
Factor 1
Inner Resilience & 
Coherence
Factor 2
Thermo 
Coherence
Alpha if item 
deleted
Item-Scale 
Correlation Self 
Regulation
1) There were times 
last week when I felt 
good
5 - 1 3.55 ± 1.04 0.774 0.724 0.415 0.889 0.531
2) I felt cold without 
reason. (inverse 
focusing)
1 – 5 4.21 ± 1.05 0.527 0.156 0.897 0.905 0.312
3) I felt pleasantly 
warm
5 - 1 3.91 ± 1.13 0.579 0.219 0.892 0.902 0.372
4) I felt my health 
was...
5 - 1 3.30 ± 1.07 0.727 0.642 0.478 0.892 0.498
5) I was able to face 
the day with 
confidence.
5 - 1 3.80 ± 1.75 0.816 0.860 0.269 0.886 0.664
6) I felt confident 
enough to solve 
problems in my daily 
life.
1 – 5 3.86 ± 1.00 0.594 0.580 0.335 0.900 0.322
7) I came up with 
good ways of solving 
new problems
1 – 5 3.67 ± 0.94 0.569 0.728 0.051 0.902 0.575
8) What I did every 
day was consistent 
with my inner wishes
5 - 1 3.38 ± 1.09 0.719 0.769 0.253 0.892 0.566
9) Deep down I felt 
secure.
1 – 5 3.68 ± 0.98 0.753 0.843 0.196 0.891 0.604
10) I felt I was moving 
in the right direction.
5 - 1 3.90 ± 0.87 0.585 0.712 0.106 0.901 0.532
Score Sum Scale Inner R. & C. Thermo C. 0,661
Cronbach-α rα = 0.91 rα = 0.91 rα = 0.85
Retest-Reliability rrt = 0.80 rrt = 0.74 rrt = 0.54
Answer possibilities with 1: low ICS, 5: high ICS, mean values, item-total-Correlation, principal component analysis result with factor 1: Inner Resilience and Coherence and factor 2: Thermo 
Coherence, Cronbach-α, test-retest-reliability, item/scale-correlation with self-regulation.Health and Quality of Life Outcomes 2009, 7:59 http://www.hqlo.com/content/7/1/59
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resilience and coherence) is measured by 8 items (range:
8 – 40) explaining 44.2% of the variance, the second prin-
cipal component (thermo coherence) is analysed by 2
items (2–10) which explains 23.0% of variance. The total
scale explains a variance of 67.2%. In this model, the fac-
tors show a largely unambiguous item analysis pattern
(table 4).
Cronbach's-α of the ICS inner resilience and coherence rα
= 0.91, retest-reliability rrt = 0.74 (p < 0.001), and Cron-
bach's-α thermo coherence rα = 0.85, retest-reliability rrt
= 0.54 (p < 0.001) (table 4).
The ICS significantly correlates with the concurrence crite-
ria Trait aR, orthostatically-circulatory regulation, rest/
activity regulation, anxiety and depression scores of the
HADS-D, KPI, and with the convergence criteria self-regu-
lation and it's subscales "achieve change in behaviour"
and "achieve satisfaction" (r = 0.30 – 0.70, each with p =
0.001). Inner resilience and coherence correlates with the
convergence criteria of r = 0.26–0.70 (p = 0.008), and
thermo coherence of r = 0.19–0.32 (p = 0.04) (table 5). Of
particular emphasis is the strong correlation between the
"inner resilience and coherence" and the SRQ scale (abil-
ity to) "Achieve satisfaction" (r = 0.70), and the strong
negative association with depression (r = 0.67) which is
sound from a conceptual point of view.
The malignant group has a lower internal, inner resilience
(both p < 0.001) and thermo coherence (p = 0.028) than
the control group, whereas with self-regulation only
"achieve satisfaction" (p = 0.012) shows a significant dif-
ference, whereas this does not hold for the subscales
"achieve change in behaviour" and the total scale (p =
0.517, p = 0.079) (table 6).
Table 5: Correlation matrix studies 1 and 2 (first survey) of internal coherence, inner resilience and coherence, thermo-coherence 
with convergence criteria
Internal Coherence (ICS) Inner Resilience & Coherence Thermo Coherence
Study 1: Inner Resilience and Coherence .97*
Study 1: Thermo Coherence .63* .50*
Study 1: Self-regulation .66* .66* .32*
Study 1: Achieve a change in behaviour .52* .52* .32*
Study 1: Achieve satisfaction .70* .70* .31*
Study 1: aR sum-scale .41* .37* .27*
Study 1: aR orthostatic-circulatory .30* .26* .19*
Study 1: aR rest/activity .44* .42* .28*
Study 1: aR digestive .09 .05 .09
Study 1: Karnofsky-Index .53* .50* .32*
Study 1: HADS Anxiety -.56* -.56* -.31*
Study 1: HADS Depression -.63* -.65* -.33*
Study 1: less cold hands even in warmer months .26* .22* .36*
Study 1: less perspiration .29* .29* .32*
Study 1: less feeling cold .34* .25* .22*
Study 2: EORTC Physical Functioning .48* .47* .20
Study 2: EORTC Role Functioning .39* .36* .23
Study 2: EORTC Emotional Functioning .73* .21 .71*
Study 2: EORTC Cognitive Functioning .36* .35* .15
Study 2: EORTC Social Functioning .31* .26 .25
Study 2: EORTC Global Health .66* .58* .47*
Study 2: EORTC Fatigue -.34* -.32* -.31*
Study 2: EORTC Sleep Disturbances -.20 -.19 -.10
Study 2: EORTC Nausea -.18 -.27 -.12
Study 2: EORTC Pain .35* .40* .11
Study 2: EORTC Dyspnea .33* .29 .44*
Study 2: EORTC Appetite loss .53* .48* .34*
Study 2: EORTC Constipation .11 .11 .19
Study 2: EORTC Diarrhea .28 .18 .25
Study 2: EORTC Financial Difficulties .25 .21 .21
* p < 0.05; correlations are presented bold.Health and Quality of Life Outcomes 2009, 7:59 http://www.hqlo.com/content/7/1/59
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Part 2 of the study
1) 18 patients who were consecutively surveyed for the B
section were included in the study, with one patient refus-
ing a third questionnaire. The questionnaires of the 17
remaining patients were available at all times and could
be evaluated without curtailing validity.
2) 27 patients with CRC were surveyed for the C section
before, during and after chemotherapy. 25 of these could
be fully evaluated at all three stages.
ICS shows relations in varying degrees to quality of life as
assessed with the EORTC (r = 0.08 – 0.71) and partly weak
to moderate correlations to the symptom scales of the
EORTC as fatigue or loss of appetite (= -0.53 – -0.28), but
also partly no correlation at all such as with constipation
etc. Of outstanding relevance is the strong correlation
between "Inner Resilience and Coherence" and EORTC's
"Emotional Functioning" (r = 0.73) and "Global Health"
(r = 0.58) (table 5).
The pooled breast cancer group and CRC group showed a
significant reduction of the ICS sum- and subscales during
chemotherapy and a significant ICS increase after finish-
ing chemotherapy (p < 0.044), with the exception of
thermo coherence 4 to 8 weeks after chemotherapy (table
6). These results are consistent with the main results of the
EORTC-QLQ C30 with a significant reduction of physical
and cognitive functioning, and a significant increase of
physical and role functioning and global health (table 7).
The above mentioned results point towards a relevant cor-
relation with quality of life and a scale sensitive to change
during chemotherapy.
Discussion
We were able to develop a short inventory on internal
coherence (ICS) with a 2-factor structure – with the factors
1) inner resilience and coherence and 2) thermo coher-
ence – with good to very good internal consistencey [21]
and a sufficient – good test-retest reliability. As the initial
expert rating for item generation was based on a previous
cancer patient symptoms list, we renounced designing the
study further patient reports and interviews. The respon-
siveness of the ICS was tested with chemotherapy treat-
ment:
As the decrease in quality of life, or the increase in adverse
events (AE) during chemotherapy respectively is well
known [22] chemotherapy sensitivity (responsiveness) in
the pooled B and C group was documented. Moreover,
compared to the SRQ according to Grossarth-Maticek, the
ICS sum scale and subscales show a better sensitivity for
tumour patients in study 1 [12]. During chemo- or radio-
therapy, the 'locus of disease control' is completely exter-
nalised, and thus measures of "self-autonomy" should be
low. Even after chemotherapy, a more depressive state of
Table 6: Mean values of ICS score of gender, age groups, cancer, breast cancer, colorectal cancer and healthy controls
Internal Coherence Scale Inner Resilience and Coherence Thermo Coherence Self regulation
STUDY 1
Gender
Female (71.9%) 36.52 (7.82) 28.67 (6.44) 7.91 (1.53) 4.05 (0.80)
Male (28.1%) 38.84 (7.17) 30.32 (5.91) 7.94 (1.46) 4.25 (0.65)
Individuals
Healthy controls (SD) 40.12 (5.12) 31.43 (4.48) 8.25 (1.30) 4.27 (0.72)
Cancer (SD) 34.23 (8.68) 26.80 (7.07) 7.60 (1.64) 3.97 (0.78)
p-value * <0.001 <0.001 0.028 0.079
STUDY 2
Breast cancer group 1 T0 36.12 (7.64) 28.41 (6.54) 7.70 (2.28)
Breast cancer group 1 T1 34.88 (7.53) 27.29 (6.25) 7.58 (1.97)
Breast cancer group 1 T2 35.35 (6.38) 27.94 (5.99) 7.41 (1.97)
Colorectal cancer T0 38.87 (6.49) 30.43 (5.81) 8.30 (1.94)
Colorectal cancer T1 35.88 (9.36) 28.47 (7.79) 7.12 (2.33)
Colorectal cancer T2 38.96 (6.75) 32.04 (5.44) 7.48 (2.27)
p-value T0 vs T1 ** 0.026 0.043 0.020
p-value T1 vs T2** 0.009 0.008 0.268
* Exact U-Test (2-side), ** Exact Wilcoxon-Test (1-side) used for pooled breast cancer and colorectal cancer and tests T0 (before chemotherapy) 
vs. T1 (1–5 days after third chemotherapy cycle) and T1 vs. T2 (4 – 8 weeks after the end of chemotherapy).
Significant differences (p < 0.05) are presented bold.Health and Quality of Life Outcomes 2009, 7:59 http://www.hqlo.com/content/7/1/59
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"self-competence" may persist in several patients, particu-
larly those with a poorer prognosis. The scale "Inner resil-
ience and coherence" in fact was strongly associated with
emotional functioning and depression and thus is
expected to be a more sensitive measure of the stressful sit-
uations, but it did not correlate with tumour stage in our
data. In study 2, compared to the EORTC quality of life
subscales with 42% significant test results, the ICS showed
in 83% significant test results. Interestingly, the EORTC
show above all chemotherapy sensitivity in physical, cog-
nitive and role functioning and not in the scales being
strongly correlated with the ICS, as emotional functioning
and only at one point in the global health scale. This
could be related to the individual self-management.
Hence, the ICS as a scale capturing the individual skills of
adaptation could be more sensitive for responsiveness as
the fixed passive emotional functioning HRQOL-meas-
ure.
High ICS, including high inner resilience and coherence
and thermo coherence level, are consistent with higher
self-regulation, autonomic regulation, quality of life,
lower depression and anxiety, along with better percep-
tion of health and quality of life (table 5), which empha-
sizes the salutogenetic significance. On the other hand,
lower ICS points towards oncological morbidity, worse
performance-index, more chemotherapeutical side effects
and increase in symptoms, as well as reduced salutoge-
netic counter-regulation (table 4). Even if thermo coher-
ence correlations coefficients to the convergence criteria
are rather moderate until low, there is face validity that
thermal comfort influence not only quality of life and a
feeling of coherence [15]. There are further data showing
that feeling cold and cold hands are well known distinc-
tive side-effects under chemotherapy [23]. To what extent
an accumulation of risk factors is involved remains to be
clarified.
Antonovsky's Sense of Coherence Scale (SOC) is a relia-
ble, valid and transculturally common instrument [24]
which surveys long-term life orientation and beliefs,
partly looking backwards, partly looking into the future,
which reflect the understandability, importance and man-
ageability of life events and stressors [8,9]. According to
Antonovsky, SOC stabilises as a trait during adolescence
[6]; however, new empirical data show changes following
interventions and life events [10,25]. It has been very
clearly shown that the focus of the SOC scale is not suita-
ble for the capture of current, clinically relevant feeling
and state of coherence for clinical questions in internal
oncological patients, because of the very backward-look-
ing, general style of questions and the face validity [24].
Our ICS scale refers to the previous week and queries per-
ception of comfort and health; questions on inner bal-
ance, particularly with respect to the ability of problem
solving, security and inner congruence and resilience in
terms of importance and manageability, and two addi-
tional items addressing perceptions of coldness/chillness
and warmth ('thermo coherence'). In the moderate corre-
lation of the two items of the thermo coherence subscale
with the inner resilience and coherence subscale and self-
regulation, we recognized a first confirmation of our
hypothesis that thermoregulation and coherence in can-
cer patients could be related. Particularly, because toler-
ance of cold is moderately associated with less
perspiration and high level thermo coherence which
could be linked with the thermo-regulatory threshold
between perspiration and vasoconstriction is depending
on circadian rhythm, vigilance, personality coherence and
gender [26]. Hence, we decided to let both subscales inte-
grated in the ICS scale, but this factor structure should be
controlled with a larger number of patients. The recorded
higher sensitivity of the ICS to differentiate between can-
cer patients and healthy controls as compared to self-reg-
ulation indicates a higher cancer sensitivity. To what
extent the postulated cancer and treatment sensitivity of
Table 7: Mean values of EORTC QLQ C30 functional scales of breast cancer and colorectal cancer
STUDY 2 Quality of Life (EORTC)
physical role emotional cognitive social Global
Breast cancer group 1 T0 78.75 (26.47) 66.67 (30.21) 54.17 (25.89) 85.42 (19.12) 67.78 (30.52) 60.42 (21.62)
Breast cancer group 1 T1 72.94 (23.27) 55.88 (30.01) 50.00 (21.73) 77.08 (22.27) 56.67 (33.21) 51.56 (22.20)
Breast cancer group 1 T2 76.86 (20.43) 64.71 (33.27) 46.08 (23.59) 68.63 (29.39) 57.84 (33.39) 58.33 (26.19)
Colorectal cancer T0 77.22 (23.42) 58.67 (38.53) 60.33 (26.60) 80.67 (19.65) 62.32 (28.07) 57.00 (22.91)
Colorectal cancer T1 69.07 (25.16) 60.00 (35.35) 63.19 (24.19) 71.33 (24.31) 67.33 (32.80) 54.71 (23.14)
Colorectal cancer T2 75.83 (19.67) 78.26 (27.26) 71.01 (25.85) 79.17 (19.19) 76.09 (25.04) 63.04 (25.48)
p-value T0 vs T1 ** 0.008 0.396 0.434 0.013 0.486 0.126
p-value T1 vs T2** 0.024 0.012 0.169 0.303 0.175 0.016
** Exact Wilcoxon-Test (1-side) used for pooled breast cancer and colorectal cancer and tests T0 (before chemotherapy) vs. T1 (1–5 days after 
third chemotherapy cycle) and T1 vs. T2 (4 – 8 weeks after the end of chemotherapy). Significant differences (p < 0.05) are presented bold.Health and Quality of Life Outcomes 2009, 7:59 http://www.hqlo.com/content/7/1/59
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the ICS in contrast to the SOC questionnaire is cancer spe-
cific, remains to be verified in further studies.
A limitation of SOC is that the three-factor structure, as
postulated by Antonovsky, could not be reproduced and
factor-loading pattern are varying significantly in the dif-
ferent languages ([27,28]. Moreover, the scale was mainly
used and validated sociologically, socio-medically and
psychiatrically [24]. As most existing studies are cross-sec-
tional studies, Antonovsky's basic assumption that the
SOC is a principal determinant of health in terms of an
ability to maintain particularly mental health despite of
significant 'stressors', has not yet been sufficiently verified.
Even if the data generated in the process show moderate
to strong negative correlation between SOC on the one
hand and anxiety, depression and distress on the other
hand, as well as positive correlations to quality of life and
subjectively gauged health, in particular mental health,
there is still controversial discussion if SOC is an inde-
pendent predictor for anxiety and depression or depends
on un-existence of anxiety and depression [29,27]. In ear-
lier prospective studies, the results were initially inconsist-
ent [30], but now there are studies which seem to have a
prognostic implication, amongst others, for cardiovascu-
lar mortality [31], for the risk of stroke [32], as well as a
46% increased prevalence of Diabetes mellitus Type 2
over a period of 17 years was associated with weak SOC
[33].
Recently a large Finnish study showed a marginally higher
12-year cancer incidence with lower SOC in elderly [34].
The EPIC-Norfolk-Study has also shown that lower SOC is
associated with an increased global mortality and cancer
mortality [31]. These results match a cross-sectional study
from Hawaii which systematically examined oncological
patients with unusually long survival rates which did not
differ from a control group with regards to their quality of
life but only with regards to their SOC levels [7]. These
results are concordant with higher life expectancy of can-
cer patients with higher self-regulation level as compared
to matched pairs – with an additional positive effect dis-
covered amongst those receiving complementary mistle-
toe therapy [35]. In fact, we can confirm strong
correlations between the SRQ and the ICS and inner resil-
ience and coherence scale and moderate with the thermo
coherence scale. Despite these interesting results which
indicate a positive influence of changing behaviour to
reach goal and well-being orientated lifestyle in the con-
text of salutogenesis on cancer incidence and progression,
the importance of the SOC in large prospective studies has
not yet been conclusively validated and requires further
validation. The clinical and prospective importance of the
new ICS remains to be clarified in future studies, but we
intend to use it to capture more appropriately inner atti-
tudes in palliative and disease-free cancer patients under
chemo or mistletoe therapy, and to measure the influence
of psychosocial support with this cancer specific individ-
ual skills of adaptation detecting tool.
There are significant limitations in our study in the lack of
parallel recording of the SOC scale in the first and second
part of the study. In unpublished data of our group, ICS
correlates in cancer patients under treatment moderately
with the SOC scales (comprehensibility: r = 0.50, mean-
ingfulness: r = 0.49, manageability: r = 0.47 (all p < 0.05)
indicating clearly the difference of the SOC, being a trait-
marker and ICS as a more clinical tool referring to the last
week. It must also be mentioned that the ten items of the
ICS only query comprehensibility indirectly. In the sec-
ond part of the study, we used a 1-side Wilcoxon test for
measuring chemotherapy sensitivity of the scale because
of clear hypothesis that ICS scores will decrease during
chemotherapy and raise afterwards, and to minimize
alpha-error due to the small patient number and because
of concomitant mistletoe therapy already reducing side-
effects of chemotherapy [36,37]. Hence, we accepted a
potential over-estimation of the beta-error. The correlative
associations between ICS and its subscales, anxiety and
depression scale are rather less strong than with the SOC;
Geyer [38] discusses to what extent the SOC would be
largely dependent on symptoms of anxiety and depres-
sion (: r = 0.42, : r = 0.53 – 0.85). Nevertheless, further
studies should clarify if ICS is more than simply the
absence of anxiety and depression.
Conclusion
The development of an Internal Coherence Scale (ICS)
was achieved with good to very good reliability. First
validity tests showed good convergence (Self-regulation),
concurrence and discriminant validity between cancer
patients and healthy control and confirmed a good
responsiveness of the ICS during cancer treatment. There-
fore, ICS could be an interesting instrument to capture the
feeling of inner coherence and resilience among cancer
patients. Further studies to confirm the scale structure and
clinical relevance are required.
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